HOME
>
薬学
>
雑誌
> 医学と薬学　80/8　2023年8月号

医学と薬学　80/8　2023年8月号

出版社：	自然科学社
発行日：	2023-07-27
分野：	薬学 > 雑誌
ISSN：	03893898
雑誌名：	医学と薬学
特集：	HIV/AIDS克服への新展開
電子書籍版：	2023-07-27 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：4～8営業日

2,200 円(税込)

章別単位での購入はできません

ブラウザ、アプリ閲覧

1,760 円(税込)

特集　HIV/AIDS克服への新展開

序文

■抗HIV治療の標石と展望
抗HIV療法の現状と課題
新たな治療戦略
　―2DRとlong acting injectableへの期待

■新薬開発の現状と未来
新たな機序によるRT阻害剤Islatravir
抗体薬への期待
根治薬開発の現状と課題

■HIV感染予防への挑戦
HIVワクチン開発の現状と今後の戦略
mRNAワクチンへの期待
PrEPへの期待

Health Care
　各種ウイルス（SARS-CoV-2・A型インフルエンザウイルス・単純ヘルペスウイルス1型）
　　に対するベンザルコニウム塩化物含有製剤の有効性評価
　乳酸菌WB2000，レスベラトロール，クロセチン複合サプリメントの眼精疲労による
　　焦点調節機能低下の改善効果
　　―ランダム化プラセボ対照二重盲検クロスオーバー試験―
　健常日本人女性のディオクリニックダイエットプログラムの実践が痩身および体組成に与える影響
　　―12週の有効性・安全性研究―

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 HIV / AIDS克服への新展開】

P.757 掲載の参考文献

1) Aboud M, Orkin C, Podzamczer D, et al : Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1 : 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV 6 : e576-e587, 2019.

PubMed

2) Osiyemi O, De Wit S, Ajana F, et al : Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1 : Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clin Infect Dis 75 : 975-986, 2022.

PubMed

3) Cahn P, Sierra Madero J, Arribas JR, et al : Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection. Aids 36 : 39-48, 2022.

PubMed

4) Pipeline report 2021 : HIV drugs in development. htb supplement 22, August 2021. https://i-base.info/htb/wp-content/uploads/2021/09/PIPELINEAug-2021.pdf (2023.4.7 アクセス)

5) Rizzardini G, Overton ET, Orkin C, et al : Long-Acting Injectable Cabotegravir+Rilpivirine for HIV Maintenance Therapy : Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr 85 : 498-506, 2020.

PubMed

6) Orkin C, Bernal Morell E, et al : Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection : week 124 results of the open-label phase 3 FLAIR study. Lancet HIV 8 : e668-e678, 2021.

PubMed

7) Overton ET, Richmond G, Rizzardini G, et al : Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection : 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study. Clin Infect Dis, ciad020, 2023.

PubMed

8) Adachi E, Ikeuchi K, Koga M, et al : Background factors in people living with HIV in Japan who switch to cabotegravir plus rilpivirine : A pilot study. J Infect Chemother 29 : 109-111, 2023.

PubMed

P.765 掲載の参考文献

1) Nakata H, Amano M, Mitsuya H, et al : Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother 51 : 2701-2708, 2007

PubMed

2) Gallois-Montbrun S, Schneider B, Veron M, et al : Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation. J Biol Chem 277 : 39953-39959, 2002.

PubMed

3) Michailidis E, Huber AD, Ryan EM, et al : 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem 289 : 24533-24548, 2014.

PubMed

4) Salie ZL, Kirby KA, Michailidis E, et al : Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA). Proc Natl Acad Sci USA 113 : 9274-9279, 2016.

PubMed

5) Kodama EI, Kohgo S, Mitsuya H, et al : 4'-Ethynyl nucleoside analogs : potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 45 : 1539-1546. 2001.

PubMed

6) Maeda K, Desai DV, Mitsuya H, et al : Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine : comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir Ther 19 : 179-189, 2014.

7) Takamatsu Y, Das D, Kohgo S, et al : The high genetic barrier of EFdA/MK-8591 stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase. Cell Chem Biol 25 : 1268-1278, 2018.

PubMed

8) Grobler JA, Nicoll-Griffith D, Lai M-T, et al : Efficacy of once-weekly MK-8591 in SIV infected rhesus macaques. 17th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, June 8-10, 2016. https://natap.org/2016/Pharm/Pharm_29.htm (2023年5月22 日アクセス)

9) Schurmann D, Rudd DJ, Zhang S et al : Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1 : an open-label, phase 1b, consecutive-panel trial. Lancet HIV 7 : e164-e172, 2020.

PubMed

10) Molina JM, Yazdanpanah Y, Saud AA, et al : Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine : a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV 8 : e324-333, 2021.

11) Molina JM, Yazdanpanah Y, Afani Saud A, et al : Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine. J Acquir Immune Defic Syndr 91 : 68-72, 2022

PubMed

12) Squires KE, Correll TA, Robertson MN, et al : Effect of islatravir on total lymphocyte and lymphocyte subset counts. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, Feb 19-22, 2023. https://natap.org/2023/CROI/croi_35.htm (2023年5月22日アクセス)

13) Markowitz M, Gettie A, Bernard LS, et al : Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques from Intrarectal Challenge with SHIV109CP3. J Infect Dis 221 : 1398-1406, 2020.

14) Matthews RP, Patel M, Barrett SE, et al : Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis : a randomized, placebo-controlled phase 1 trial. Nature medicine 27 : 1712-1717, 2021.

PubMed

15) Matthews RP, Zang X, Barrett SE, et al : A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection. J Acquir Immune Defic Syndr 92 : 310-316, 2023.

PubMed

P.773 掲載の参考文献

1) Matsushita S, Robert-Guroff M, Rusche J, et al : Characterization of human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol 62 : 2107-2114, 1988.

PubMed

2) Emini EA, Schleif WA, Nunberg JH, et al : Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355 : 728-730, 1992.

PubMed

3) Hsu DC, Mellors JW, Vasan S, et al : Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission? Front Immunol 12 : 710044, 2021.

PubMed

4) Deeks S, Lewin SR, Zacks J, et al : International AIDS Society global scientific strategy : towards an HIV cure. Nat Med 22 : 839-850, 2016.

5) Shingai M, Nishimura Y, Klein F, et al : Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 : 277-280, 2013.

PubMed

6) Nishimura Y, Gautam R, Chun TW, et al : Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543 : 559-563, 2017.

PubMed

7) Matsushita S, Yoshimura K, Ramirez KP, et al : Passive transfer of neutralizing monoclonal antibody KD-247 reduces plasma viral load in patients chronically infected with HIV-1. AIDS 29 : 453-462, 2015.

PubMed

8) Bar KJ, Sneller MC, Harrison LJ, et al : Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 375 : 2037-2050, 2016.

PubMed

9) Mendoza P, Gruell H, Nogueira L, et al : Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561 : 479-484, 2018.

PubMed

10) Niessl J, Baxter AE, Mendoza P, et al : Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med 26 : 222-227, 2020.

PubMed

11) Gaebler C, Nogueira L, Stoffel E, et al : Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606 : 368-374, 2022.

PubMed

12) Sneller MC, Blazkova J, Justement JS, et al : Combination anti-HIV antibodies provide sustained virological suppression. Nature 606 : 375-381, 2022.

PubMed

13) Julg B, Stephenson KE, Wagh K, et al : Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1 : a phase 1 clinical trial. Nature Med 28 : 1288-1296, 2022.

PubMed

14) Leone P, Ferro A, Rolle CP, et al : VH3810109 (N6LS) Reduces Viremia Across a Range of Doses in ART-Naive Adults Living with HIV : Proof of Concept Achieved in the Phase IIa BANNER (207959, NCT04871113) Study. Presented at AIDS 2022.

15) Eron JJ, Little SR, Crofoot G, et al : Lenacapavir with bNAbs GS-5423 and GS-2872 dosed every 6 months in people with HIV. Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, Feb 19-22, 2023. https://natap.org/2023/CROI/croi_36.htm (2023年6月12日アクセス)

P.779 掲載の参考文献

1) Barre-Sinoussi F, Chermann JC, Rey F, et al : Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 : 868-871, 1983.

2) Gallo RC, Sarin PS, Gelmann EP, et al : Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220 : 865-867, 1983.

PubMed

3) Mitsuya H, Weinhold KJ, Furman PA, et al : 3'-Azido-3'-deoxythymidine (BW A509U) : an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82 : 7096-7100, 1985.

PubMed

4) Descours B, Petitjean G, Lopez-Zaragoza JL, et al : CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature 543 : 564-567, 2017.

PubMed

5) Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, et al : CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Sci Transl Med 10 : eaar6759, 2018.

6) Laird GM, Eisele EE, Rabi SA, et al : Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 9 : e1003398, 2013.

PubMed

7) Matsuda K, Islam S, Takada T, et al : A widely-distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. Cell Rep Methods 1 : 100122, 2021.

PubMed

8) Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9 : 727-728, 2003.

PubMed

9) Katlama C, Deeks SG, Autran B, et al : Barriers to a cure for HIV : new ways to target and eradicate HIV-1 reservoirs. Lancet 381 : 2109-2117, 2013.

PubMed

10) Kim Y, Anderson JL, Lewin SR : Getting the "Kill" into "Shock and Kill" : Strategies to Eliminate Latent HIV. Cell Host Microbe 23 : 14-26, 2018.

PubMed

11) Hattori SI, Matsuda K, Tsuchiya K, et al : Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. Front Microbiol 9 : 2022, 2018.

PubMed

12) Bullen CK, Laird GM, Durand CM, et al : New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20 : 425-429, 2014.

PubMed

13) Laird GM, Bullen CK, Rosenbloom DI, et al : Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125 : 1901-1912, 2015.

PubMed

14) Matsuda K, Kobayakawa T, Tsuchiya K, et al : Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal. J Biol Chem 294 : 116-129, 2019.

PubMed

15) Rodari A, Darcis G, Van Lint CM : The current status of latency reversing agents for HIV-1 remission. Annual Review of Virology 8 : 491-514, 2021.

PubMed

16) Tamamura H, Bienfait B, Nacro K, et al : Conformationally constrained analogues of diacylglycerol (DAG). 17. Contrast between sn-1 and sn-2 DAG lactones in binding to protein kinase C. J Med Chem 43 : 3209-3217, 2000.

PubMed

17) Newton AC : Protein kinase C : structure, function, and regulation. J Biol Chem 270 : 28495-28498, 1995.

PubMed

18) Jiang G, Mendes EA, Kaiser P, et al : Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog 11 : e1005066, 2015.

PubMed

19) Gutierrez C, Serrano-Villar S, Madrid-Elena N, et al : Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy. AIDS 30 : 1385-1392, 2016.

PubMed

20) Lucera MB, Tilton CA, Mao H, et al : The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events. J Virol 88 : 10803-10812, 2014.

PubMed

21) Ho YC, Shan L, Hosmane NN, et al : Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155 : 540-551, 2013.

PubMed

22) Hutter G, Nowak D, Mossner M, et al : Long-term control of HIV by CCR5 Delta32/Delta32 stemcell transplantation. N Engl J Med 360 : 692-698, 2009.

PubMed

23) Gupta RK, Abdul-Jawad S, McCoy LE, et al : HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 568 : 244-248, 2019.

24) Fidler S, Stohr W, Pace M, et al : RIVER trial study group. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial) : a phase 2, randomised trial. Lancet 395 : 888-898, 2020.

25) Borducchi EN, Liu J, Nkolola JP, et al : Anti-body and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563 : 360-364, 2018.

26) Gunst JD, Pahus MH, Rosis-Umbert M, et al : Impact of 3BNC117 and Romidepsin treatment at ART initiation on HIV-1. Conference on Retroviruses and Opportunistic Infections. Conference on Retroviruses and Opportunistic Infections Virtual, February 12-16, 2022. https://www.natap.org/2022/CROI/croi_54.htm (2022年5月18日アクセス)

27) Ruane P, Daar E, Workowski K, et al : Safety & pharmacokinetics of GS-9722 in HIV-negative participants and people with HIV. Conference on Retroviruses and Opportunistic Infections Boston USA, March 8-11, 2020. https://www.natap.org/2020/CROI/croi_ 06.htm (2022年5月18日アクセス)

P.787 掲載の参考文献

1) Buchbinder SP, Mehrotra DV, Duerr A, et al : Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study) : a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 : 1881-1893, 2008.

PubMed

2) Gray GE, Allen M, Moodie Z, et al : Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa : a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11 : 507-515, 2011.

PubMed

3) Hu H, Eller MA, Zafar S, et al : Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci USA 111 : 13439-13444, 2014.

PubMed

4) Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al : Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 : 2209-2220, 2009.

PubMed

5) Haynes BF, Gilbert PB, McElrath MJ, et al : Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366 : 1275-1286, 2012.

6) Gray GE, Bekker LG, Laher F, et al : Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med 384 : 1089-1100, 2021.

PubMed

7) Gray GE : Phase IIb Efficacy Trial of Mosaic HIV-1 Vaccine Regimen in African Women : (Imbokodo). 29th Conference on Retroviruses and Opportunistic Infections Virtual, February 12-16, 2022. https://www.natap.org/2022/CROI/croi_159a.htm (2023年5月19日アクセス)

8) Buchbinder SP : Results from the MOSAICO HIV Vaccine Trial and Future Directions for HIV Vaccines. 30th Conference on Retroviruses and Opportunistic Infections, 2023. https://www.croiwebcasts.org/s/2023croi/SPECIAL%20SESSION-1 (2023年5月19日アクセス)

9) Sanders RW, Moore JP : Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev 275 : 161-182, 2017.

PubMed

10) Pauthner M, Havenar-Daughton C, Sok D, et al : Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity 46 : 1073-1088.e6, 2017.

11) Chen CW, Saubi N, Joseph-Munne J : Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines. Front Immunol 11 : 573157, 2020.

PubMed

12) Ishii H, Nakamura-Hoshi M, Shu T, et al : Sendai virus particles carrying target virus glycoproteins for antibody induction. Vaccine 40 : 2420-2431, 2022.

PubMed

13) Haynes BF, Wiehe K, Borrow P, et al : Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol 23 : 142-158, 2023.

PubMed

14) Leggat DJ, Cohen KW, Willis JR, et al : Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378 : eadd6502, 2022.

PubMed

15) Ishii H, Terahara K, Nomura T, et al : Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells. Mol Ther 30 : 2048-2057, 2022.

16) Ishii H, Matsuoka S, Nomura T, et al : Association of lymph-node antigens with lower Gag-specific central-memory and higher Env-specific effector-memory CD8 (+) T-cell frequencies in a macaque AIDS model. Sci Rep 6 : 30153, 2016.

17) Mothe B, Hu X, Llano A, et al : A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med 13 : 60, 2015.

18) Gaiha GD, Rossin EJ, Urbach J, et al : Structural topology defines protective CD8+ T cell epitopes in the HIV proteome. Science 364 : 480-484, 2019.

19) Douek DC, Brenchley JM, Betts MR, et al : HIV preferentially infects HIV-specific CD4+ T cells. Nature 417 : 95-98, 2022.

20) Terahara K, Ishii H, Nomura T, et al : Vaccine-induced CD107a+ CD4+ T cells are resistant to depletion following AIDS virus infection. J Virol 88 : 14232-14240, 2014.

PubMed

21) Chamcha V, Reddy PBJ, Kannanganat S, et al : Strong TH1-biased CD4 T cell responses are associated with diminished SIV vaccine efficacy. Sci Transl Med 11 : eaav1800, 2019.

PubMed

22) Ishii H, Terahara K, Nomura T, et al : A Novel Immunogen Selectively Eliciting CD8+ T Cells but Not CD4+ T Cells Targeting Immunodeficiency Virus Antigens. J Virol 94 : e01876-19, 2021.

P.798 掲載の参考文献

1) UNAIDS. Global HIV & AIDS statistics-Fact sheet 2022. https://www.unaids.org/en/resources/fact-sheet (2023年4月4日アクセス)

2) GBD 2019 Diseases and Injuries Collaborators : Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396 : 1204-1222, 2020.

PubMed

3) Excler JL, Saville M, Berkley S, et al : Vaccine development for emerging infectious diseases. Nat Med 27 : 591-600, 2021.

PubMed

4) Tian Y, Hu D, Li Y, et al : Development of therapeutic vaccines for the treatment of diseases. Mol Biomed 3 : 40, 2022.

PubMed

5) Derking R, Sanders RW : Structure-guided envelope trimer design in HIV-1 vaccine development : a narrative review. J Int AIDS Soc 24 (Suppl 7) : e25797, 2021.

6) Cuevas JM, Geller R, Garijo R, et al : Extremely High Mutation Rate of HIV-1 In Vivo. PLoS Biol 13 : e1002251, 2015.

PubMed

7) Prabakaran P, Dimitrov AS, Fouts TR, et al : Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Adv Pharmacol 55 : 33-97, 2007.

8) Wyatt R, Kwong PD, Desjardins E, et al : The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 : 705-711, 1998.

9) Raska M, Takahashi K, Czernekova L, et al : Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285 : 20860-20869, 2010.

PubMed

10) Lee JH, Crotty S : HIV vaccinology : 2021 update. Semin Immunol 51 : 101470, 2021.

PubMed

11) McCormack S, Dunn DT, Desai M, et al : Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD) : effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387 : 53-60, 2016.

PubMed

12) Landovitz RJ, Donnell D, Clement ME, et al : Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 385 : 595-608, 2021.

PubMed

13) Delany-Moretlwe S, Hughes JP, Bock P, et al : Cabotegravir for the prevention of HIV-1 in women : results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399 : 1779-1789, 2022.

PubMed

14) Xiridou M, Hoornenborg E : Long-acting PrEP : new opportunities with some drawbacks. Lancet HIV 10 : e213-e215, 2023.

PubMed

15) Jetzt AE, Yu H, Klarmann GJ, et al : High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 74 : 1234-1240, 2000.

PubMed

16) Ng'uni T, Chasara C, Ndhlovu ZM : Major Scientific Hurdles in HIV Vaccine Development : Historical Perspective and Future Directions. Front Immunol 11 : 590780, 2020.

PubMed

17) Wei X, Decker JM, Wang S, et al : Antibody neutralization and escape by HIV-1. Nature 422 : 307-312, 2003.

PubMed

18) Kwong PD, Wyatt R, Robinson J, et al : Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 : 648-659, 1998.

19) Kleinman AJ, Pandrea I, Apetrei C : So Pathogenic or So What? -A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research. Viruses 14 : 135, 2022.

20) Bar KJ, Coronado E, Hensley-McBain T, et al : Simian-Human Immunodeficiency Virus SHIV. CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. J Virol 93 : e00372-19, 2019.

PubMed

21) Roark RS, Li H, Williams WB, et al : Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 371 : eabd2638, 2021.

PubMed

22) Barouch DH : Challenges in the development of an HIV-1 vaccine. Nature 455 : 613-619, 2008.

PubMed

23) Flynn NM, Forthal DN, Harro CD, et al ; rgp120 HIV Vaccine Study Group : Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 : 654-665, 2005.

24) Pitisuttithum P, Gilbert P, Gurwith M, et al ; Bangkok Vaccine Evaluation Group : Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194 : 1661-1671, 2006.

PubMed

25) Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al : Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361 : 2209-2220, 2009.

PubMed

26) Gray GE, Bekker LG, Laher F, et al : Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med 384 : 1089-1100, 2021.

PubMed

27) National Institute of Allergy and Infectious Disease. Experimental HIV Vaccine Regimen Ineffective in Preventing HIV. https://www.niaid.nih.gov/news-events/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv (2023年4月4日アクセス)

28) Buchbinder SP, Mehrotra DV, Duerr A, et al : Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study) : a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 : 1881-1893, 2008.

PubMed

29) Gray GE, Allen M, Moodie Z, et al : Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa : a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis 11 : 507-515, 2011.

PubMed

30) Hammer SM, Sobieszczyk ME, Janes H, et al : Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 369 : 2083-2092, 2013

PubMed

31) Barouch DH, O'Brien KL, Simmons NL, et al : Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16 : 319-323, 2010.

PubMed

32) Barouch DH, Picker LJ : Novel vaccine vectors for HIV-1. Nat Rev Microbiol 12 : 765-771, 2014.

PubMed

33) IAVI News & Resources : IAVI statement on results from Phase IIb Imbokodo HIV vaccine clinical trial. September 1, 2021. https://www.iavi.org/news-resources/features/iavi-statement-onresults-from-phase-iib-imbokodo-hiv-vaccineclinical-trial (2023年4月4日アクセス)

34) Johnson & Johnson : Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial. January 18, 2023. https://www.jnj.com/janssen-and-global-partners-to-discontinuephase-3-mosaico-hiv-vaccine-clinical-trial (2023年4月4日アクセス)

35) Mendez AC, Rodriguez-Rojas C, Del Val M : Vaccine vectors : the bright side of cytomegalovirus. Med Microbiol Immunol 208 : 349-363, 2019.

PubMed

36) Fruh K, Picker L : CD8+ T cell programming by cytomegalovirus vectors : applications in prophylactic and therapeutic vaccination. Curr Opin Immunol 47 : 52-56, 2017.

PubMed

37) Hansen SG, Marshall EE, Malouli D, et al : A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Sci Transl Med 11 : eaaw2607, 2019

PubMed

38) Fausther-Bovendo H, Kobinger GP : Pre-existing immunity against Ad vectors : humoral, cellular, and innate response, what's important? Hum Vaccin Immunother 10 : 2875-2884, 2014.

PubMed

39) Michael NL : Rare serotype adenoviral vectors for HIV vaccine development. J Clin Invest 122 : 25-27, 2012.

PubMed

40) Folegatti PM, Ewer KJ, Aley PK, et al : Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396 : 467-478, 2020.

PubMed

41) Hayton EJ, Rose A, Ibrahimsa U, et al : Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One 9 : e101591, 2014.

42) Zhou D, Cun A, Li Y, et al : A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 14 : 662-672, 2006.

43) Iampietro MJ, Larocca RA, Provine NM, et al : Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors. J Virol 92 : e00159-18, 2018.

PubMed

44) Chaudhary N, Weissman D, Whitehead KA : mRNA vaccines for infectious diseases : principles, delivery and clinical translation. Nat Rev Drug Discov 20 : 817-838, 2021.

PubMed

45) Tian Y, Deng Z, Yang P : mRNA vaccines : A novel weapon to control infectious diseases. Front Microbiol 13 : 1008684, 2022.

PubMed

46) El Sahly HM, Baden LR, Essink B, et al : Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med 385 : 1774-1785, 2021.

47) Polack FP, Thomas SJ, Kitchin N, et al : Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383 : 2603-2615, 2020.

PubMed

48) Zheng C, Shao W, Chen X, et al : Real-world effectiveness of COVID-19 vaccines : a literature review and meta-analysis. Int J Infect Dis 114 : 252-260, 2022.

PubMed

49) Pardi N, Hogan MJ, Porter FW, et al : mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov 17 : 261-279, 2018.

PubMed

50) Cagigi A, Lore K : Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines (Basel) 9 : 61, 2021.

PubMed

51) Steichen JM, Kulp DW, Tokatlian T, et al : HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45 : 483-496, 2016.

PubMed

52) Whitley J, Zwolinski C, Denis C, et al : Development of mRNA manufacturing for vaccines and therapeutics : mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Transl Res 242 : 38-55, 2022.

PubMed

53) Wu X, Yang ZY, Li Y et al : Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329 : 856-861, 2010.

54) Hraber P, Seaman MS, Bailer RT, et al : Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28 : 163-169, 2014.

PubMed

55) Spencer DA, Shapiro MB, Haigwood NL, et al : Advancing HIV Broadly Neutralizing Antibodies : From Discovery to the Clinic. Front Public Health 9 : 690017, 2021.

56) Klein F, Mouquet H, Dosenovic P, et al : Antibodies in HIV-1 vaccine development and therapy. Science 341 : 1199-1204, 2013.

57) Zhou T, Georgiev I, Wu X, et al : Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329 : 811-817, 2010.

PubMed

58) Shingai M, Donau OK, Plishka RJ, et al : Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med 211 : 2061-2074, 2014.

PubMed

59) Saunders KO, Pegu A, Georgiev IS, et al : Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol 89 : 5895-5903, 2015.

PubMed

60) Mayer KH, Seaton KE, Huang Y, et al : Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults : Results of a phase 1 r andomized trial. PL oS Med 14 : e1002435, 2017.

PubMed

61) Ledgerwood JE, Coates EE, Yamshchikov G, et al : Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182 : 289-301, 2015.

PubMed

62) Pardi N, Secreto AJ, Shan X, et al : Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8 : 14630, 2017.

PubMed

63) Pardi N, Hogan MJ, Naradikian MS, et al : Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med 215 : 1571-1588, 2018.

PubMed

64) Zhang P, Narayanan E, Liu Q, et al : A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med 27 : 2234-2245, 2021.

65) Narayanan E, Falcone S, Elbashir SM, et al : Rational Design and In Vivo Characterization of mRNA-Encoded Broadly Neutralizing Antibody Combinations against HIV-1. Antibodies (Basel) 11 : 67, 2022.

PubMed

66) Corey L, Gilbert PB, Juraska M, et al : Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 384 : 1003-1014, 2021.

PubMed

67) Jardine J, Julien JP, Menis S, et al : Rational HIV immunogen design to target specific germline B cell receptors. Science 340 : 711-716, 2013.

PubMed

68) McGuire AT, Hoot S, Dreyer AM, et al : Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med 210 : 655-663, 2013.

PubMed

69) Jardine JG, Kulp DW, Havenar-Daughton C, et al : HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 : 1458-1463, 2016.

PubMed

70) Escolano A, Steichen JM, Dosenovic P, et al : Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166 : 1445-1458.e12, 2016.

71) Briney B, Sok D, Jardine JG, et al : Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166 : 1459-1470.e11, 2016.

72) Tian M, Cheng C, Chen X, et al : Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166 : 1471-1484.e18, 2016.

73) Medina-Ramirez M, Garces F, Escolano A, et al : Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med 214 : 2573-2590, 2017.

PubMed

74) Steichen JM, Lin YC, Havenar-Daughton C, et al : A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. Science 366 : eaax4380, 2019.

75) Parks KR, MacCamy AJ, Trichka J, et al : Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization. Cell Rep 29 : 3060-3072.e7, 2019.

76) Chen X, Zhou T, Schmidt SD, et al : Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity 54 : 324-339.e8, 2021.

77) Leggat DJ, Cohen KW, Willis JR, et al : Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378 : eadd6502, 2022.

PubMed

78) Sanders RW, Derking R, Cupo A, et al : A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9 : e1003618, 2013.

79) Scharf L, Wang H, Gao H, et al : Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell 162 : 1379-1390, 2015.

PubMed

P.809 掲載の参考文献

1) Grant RM, Lama JR, Anderson PL, et al : Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363 : 2587-2599, 2010.

PubMed

2) Molina JM, Capitant C, Spire B, et al : On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med 373 : 2237-2246, 2015.

PubMed

3) McCormack S, Dunn DT, Desai M, et al : Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD) : effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 387 : 53-60, 2016.

PubMed

4) Mayer KH, Molina JM, Thompson MA, et al : Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER) : primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet 396 : 239-254, 2020.

PubMed

5) Landovitz RJ, Donnell D, Clement ME, et al : Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med 385 : 595-608, 2021.

PubMed

6) CDC : Preexposure prophylaxis for the prevention of HIV infection in the United States-2021 update. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf (2023年5月16日アクセス)

7) 令和2～4年度厚生労働省科学研究費補助金 (エイズ対策政策研究事業) 「HIV感染症の曝露前及び曝露後の予防投薬の提供体制の整備に資する研究」 (研究分担者 : 生島嗣, 研究代表者 : 水島大輔) : 日本におけるHIV感染予防のための曝露前予防 (PrEP) -利用者ガイド-【第一版】. https://jaids.jp/wpsystem/wp-content/uploads/2022/11/uderguide-matome-1Pver.pdf (2023年5月16日アクセス)

8) 令和2～4年度厚生労働科学研究費補助金 (エイズ対策政策研究事業) 「HIV 感染症の曝露前及び曝露後の予防投薬の提供体制の整備に資する研究」 (研究分担者 : 生島嗣, 研究代表者 : 水島大輔) : 「セックスライフとPrEPについてのアンケート調査」報告書. https://prep.ptokyo.org/wp/wp-content/uploads/2022/04/prepinjapan_report_R3.pdf (2023年5月16日アクセス)

9) Mizushima D, Takano M, Ando N, et al : A four-year observation of HIV and sexually transmitted infections among men who have sex with men before and during pre-exposure prophylaxis in Tokyo. J Infect Chemother 28 : 762-766, 2022.

10) Jenness SM, Weiss KM, Goodreau SM, et al : Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men : A Modeling Study. Clin Infect Dis 65 : 712-718, 2017.

PubMed

11) Traeger MW, Guy R, Asselin J, et al : Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation : an analysis of sentinel surveillance data. Lancet Infect Dis 22 : 1231-1241, 2022.

PubMed

12) CDC : Sexually Transmitted Infections Treatment Guidelines, 2021.

13) Mizushima D, Takano M, Uemura H, et al : High prevalence and incidence of rectal Chlamydia infection among men who have sex with men in Japan. PLoS One 14 : e0220072, 2019.

PubMed

14) Peel J, Chow EPF, Denham I, et al : Clinical Presentation of Incident Syphilis Among Men Who Have Sex with Men Taking HIV Pre-Exposure Prophylaxis in Melbourne, Australia. Clin Infect Dis 73 : e934-e937, 2021.

PubMed

15) Ando N, Mizushima D, Watanabe K, et al : Modified self-obtained pooled sampling to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in men who have sex with men. Sex Transm Infect 97 : 324-328, 2021.

PubMed

16) Petousis-Harris H, Paynter J, Morgan J, et al : Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand : a retrospective case-control study. Lancet 390 : 1603, 2017.

17) Abara WE, Bernstein KT, Lewis FMT, et al : Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea : a retrospective observational study. Lancet Infect Dis 22 : 1021-1029, 2022.

PubMed

【Health Care】

P.815 掲載の参考文献

1) World Health Organization. Origin of SARS-CoV-2. 26 March 2020.

2) 厚生労働省, 経済産業省, 消費者庁 : 新型コロナウイルスの消毒・除菌方法について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/syoudoku_00001.html. 〔参照2023年5月10日〕

3) 南貴大, 岡村善裕, 多賀康仁 : 各種ウイルス (SARS-CoV-2・A型インフルエンザウイルス・ノロウイルス代替ウイルス) に対するエタノール含有製剤の有効性評価. 医学と薬学 79 (5) : 697-702, 2022.

4) Kratzel A, Todt D, V'kovski P, et al : Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. Emerg Infect Dis 26 (7) : 1592-1595, 2020.

PubMed

5) 厚生労働省. インフルエンザの発生状況. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou01/houdou.html〔参照2023年5月10日〕

6) 第十四改正日本薬局方解説書. 塩化ベンザルコニウム, C-473, 廣川書店, 東京, 2001.

P.830 掲載の参考文献

1) 総務省 : 情報通信統計世界のインターネット利用者総数の推移. https://www.soumu.go.jp/johotsusintokei/field/tsuushin08.html

2) Amy L Sheppard, James S Wolffsohn : Wolffsohn. Digital eye strain : prevalence, measurement and amelioration. BMJ Open Ophthalmol 3 (1) : p. e000146, 2018.

3) Coles-Brennan C, A Sulley, G Young : Management of digital eye strain. Clin Exp Optom 102 (1) : 18-29, 2019.

4) American Optometric Association : Computer vision syndrome. https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/computer-vision-syndrome?sso=y

5) Joan K Portello, Mark Rosenfield, Yuliya Bababekova, et al : Computer-related visual symptoms in office workers. Ophthalmic Physiol Opt 32 (5) : 375-382, 2012.

PubMed

6) 厚生労働省 : 平成20年技術革新と労働に関する実態調査結果の概況. https://www.mhlw.go.jp/toukei/itiran/roudou/saigai/anzen/08/index.html

7) Negishi K, Ayaki M : Presbyopia developed earlier during the COVID-19 pandemic. PLoS One 16 (11) : e025914, 2021.

8) 小手川泰枝, 原直人, 大野晃司, 他 : 眼精疲労を有する若年visual display terminal (VDT) 作業者に対する屈折適正矯正による調節反応と自覚症状の変化について. 日本眼科学会雑誌 112 (4) : 376-381, 2008.

Medical*Online

9) Xuan B, Zhou YH, Li N, et al : Effects of crocin analogs on ocular blood flow and retinal function. J Ocul Pharmacol Ther 15 (2) : 143-152, 1999.

PubMed

10) Nagaki Y, Hayasaka S, Abe T, et al : Effects of Oral Administration of Gardeniae fructus Extract and Intravenous Injection of Crocetin on Lipopolysaccharide- and Prostaglandin E2-induced Elevation of Aqueous Flare in Pigmented Rabbits. Am J Chin Med 3 (5) : 729-738, 2003.

PubMed

11) 梶田雅義, 海貝尚史, 仲野隆久, 他 : クロセチン高含有クチナシ抽出物による眼精疲労改善効果. 視覚と科学 28 : 77-84, 2007.

12) Baur J A, Sinclair D A : Therapeutic potential of resveratrol : the in vivo evidence. Nat Rev Drug Discov 5 (6) : 493-506, 2006.

PubMed

13) 坪田一男 : レスベラトロールの基礎と応用 ≪普及版≫. バイオテクノロジーシリーズ 2019, シーエムシー出版, 東京, 2019.

14) Kubota S, Kurihara T, Ebinuma M, et al : Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am J Pathol 177 (4) : 1725-1731, 2010.

PubMed

15) Kubota S, Ozawa Y, Kurihara T, et al : Roles of AMP-activated protein kinase in diabetes-induced retinal inflammation. Invest Ophthalmol Vis Sci 52 (12) : 9142-9148, 2011.

PubMed

16) Nagai N, Kubota S, Tsubota K, et al : Resveratrol prevents the development of choroidal neovascularization by modulating AMP-activated protein kinase in macrophages and other cell types. J Nutr Biochem 25 (11) : 1218-1225, 2014.

PubMed

17) Kawashima M, Nakamura S, Izuta Y, et al : Dietary Supplementation with a Combination of Lactoferrin, Fish Oil, and Enterococcus faecium WB2000 for Treating Dry Eye : A Rat Model and Human Clinical Study. Ocul Surf 14 (2) : 255-263, 2016.

PubMed

18) Nagashima H, Sasaki N, Amano S, et al : Oral administration of resveratrol or lactic acid bacterium improves lens elasticity. Sci Rep 11 (1) : 2174, 2021.

PubMed

19) 梶田雅義, 落谷大輔, 松岡成郎, 他 : 健康成人を対象としたクロセチン・イチョウ葉エキス配合サプリメント摂取による視機能への影響ランダム化二重盲検プラセボ対照クロスオーバー比較試験. 薬理と治療 49 (3) : 401-411, 2021.

Medical*Online

20) 海貝尚史, 齋藤信裕, 山下慎一郎, 他 : Visual Display Terminal作業に伴う調節機能低下に対するクロセチン摂取の影響ランダム化二重盲検プラセボ対照クロスオーバー試験. 日本補完代替医療学会誌 14 (1) : 9-16, 2017.

21) 鈴木説子, 梶田雅義, 加藤桂一郎 : 調節微動の高周波成分による調節機能の評価. 視覚の科学 22 (3) : 93-97, 2001.

22) Mori K, Torii H, Fujimoto S, et al : The Effect of Dietary Supplementation of Crocetin for Myopia Control in Children : A Randomized Clinical Trial. J Clin Med 8 (8) : 1179, 2019.

23) H ui-Fang Li Shih-Ann Chen, Sheng-Nan Wu : Evidence for the stimulatory effect of resveratrol on Ca (2+) -activated K+ current in vascular endothelial cells. Cardiovasc Res 45 (4) : 1035-1045, 2000.

24) Garrigue P, Mounien L, Champion S, et al : Long-term administration of resveratrol at low doses improves neurocognitive performance as well as cerebral blood flow and modulates the inflammatory pathways in the brain. J Nutr Biochem 97 : 108786, 2021.

25) Kubota S, Kurihara T, Mochimaru H, et al : Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 50 (7) : 3512-3519, 2009.

PubMed

26) Wang S, Moonasar N, Xiao X, et al : Effect of Resveratrol-Based Nutritional Supplement on Choroidal Thickness : A Pilot Study. Curr Eye Res 41 (10) : 1339-1345, 2016.

PubMed

27) Doganay S, Borazan M, Iraz M, et al : The effect of resveratrol in experimental cataract model formed by sodium selenite. Curr Eye Res 31 (2) : 147-153, 2006.

PubMed

28) Nakagawa H, Miyazaki T : Beneficial effects of antioxidative lactic acid bacteria. AIMS Microbiol 3 (1) : 1-7, 2017.

PubMed

29) Lin X, Xia Y, Wang G, et al : Lactic Acid Bacteria With Antioxidant Activities Alleviating Oxidized Oil Induced Hepatic Injury in Mice. Front Microbiol 9 : 2684, 2018.

PubMed

30) Ichikawa S, MIYAKE M, FUJII R, et al : Orally administered Lactobacillus paracasei KW3110 induces in vivo IL-12 production. Biosci Biotechnol Biochem 73 (7) : 1561-1565, 2009.

PubMed

31) Wakabayashi H, Nariai C, Takemura F, et al : Dietary supplementation with lactic acid bacteria attenuates the development of atopic-dermatitis-like skin lesions in NC/Nga mice in a strain-dependent manner. Int Arch Allergy Immunol 145 (2) : 141-151, 2008.

32) Morita Y, Jounai K, Sakamoto A, et al : Long-term intake of Lactobacillus paracasei KW3110 prevents age-related chronic inflammation and retinal cell loss in physiologically aged mice. Aging (Albany NY) 10 (10) : 2723-2740, 2018.

PubMed

33) 畑野優子, 鈴木奈央, 米田雅裕, 他 : 乳酸菌配合歯磨剤 (アバンビーズ(R)) の口腔衛生改善効果についての臨床研究. 日本歯科保存学雑誌 55 (3) : 219-226, 2012.

Medical*Online

34) 梶田雅義 : 【三次元画像と眼】調節応答と微動. 眼科 40 (2) : 169-177, 1998.

35) Duane A : Studies in Monocular and Binocular Accommodation, with Their Clinical Application. Trans Am Ophthalmol Soc 20 : 132-157, 1922.

PubMed

36) Tsuneyoshi Y, Higuchi A, Negishiet K, et al : Suppression of presbyopia progression with pirenoxine eye drops : experiments on rats and non-blinded, randomized clinical trial of efficacy. Sci Rep 7 (1) : 6819, 2017.

37) Radhakrishnan H, Charman WN : Age-related changes in static accommodation and accommodative miosis. Ophthalmic Physiol Opt 27 (4) : 342-352, 2007.

PubMed

P.840 掲載の参考文献

1) 厚生労働省 : 令和元年国民健康・栄養調査 (2019).

2) 厚生労働省 : 健康日本21 (第二次). 平成24年7月10日厚生労働省告示730号. (2012).

3) 医療法人社団翔友会品川美容外科 : ダイエットに関する意識調査. 2017年3月2日発表. https://prtimes.jp/main/html/rd/p/000000001.000024208.html〔最終アクセス2023年6月23日〕

4) 村上雅子, 原毅, 今井昇 : 2型糖尿病における持続性GLP-1受容体作動薬デュラグルチドの有用性 : 肥満度別検討と長期成績. 糖尿病 64 : 547-554, 2021.

5) 高本偉碩, 門脇孝 : 糖尿病 (インクレチン関連薬とSGLT2阻害薬). 心臓 49 : 449-454, 2017.

Medical*Online

6) 常見亜佐子, 綿田裕孝 : メトホルミン. Pharma Medica 36 : 21, 2018.

Medical*Online

7) 森脇紀親, 赤堀みつる, 杉井寛 : 世界初の経口GLP-1受容体作動薬リベルサス(R) の開発. Drug Delivery System 37 : 169-173, 2022.

8) 独立行政法人医薬品医療機器総合機構一般用・要始動医薬品添付文書, ツムラ漢方防風通聖散エキス顆粒. https://www.pmda.go.jp/PmdaSearch/otcDetail/ResultDataSetPDF/460026_J0601010604_09_01/A 最終アクセス2023/6/23〕

9) 独立行政法人医薬品医療機器総合機構 : 一般用・要始動医薬品添付文書, ツムラ漢方防已黄耆湯エキス顆粒. https://www.pmda.go.jp/PmdaSearch/otcDetail/ResultDataSetPDF/460026_J0601010556_07_01/A〔最終アクセス2023/6/23〕

10) 立花克郎, 入江豊, 小川皓一 : 超音波の治療への応用. 超音波医学 33 : 631-639, 2006.

Medical*Online

11) 小路直, 日暮太朗, 川上正能, 他 : HIFUを用いた前立腺癌局所療法の可能性. Japanese Journal of Endourology 28 : 224-231, 2015.

Medical*Online

12) 梅村晋一郎 : HIFU (高密度焦点式超音波) 療法の基礎. 医学のあゆみ 238 : 163-168. 2011.

Medical*Online

13) 綾部誠 : 痩身機器冷却脂肪融解治療医療機器クールスカルプティングの効果と実際 (特集美容肥満治療と美容目的の痩身機器 : その理論と実際). 形成外科 63 : 693-700, 2020.

14) 柳井久江 : 4 Steps エクセル統計第4版. オーエムエス出版, 東京, 2015.

15) 上野浩晶, 中里雅光 : GLP-1受容体作動薬の体重減少効果. 糖尿病 60 : 570-572, 2017.

16) 杉井寛, 松村順子, 井上明弘, 他 : ヒトGLP-1アナログ製剤リラグルチド (ビクトーザ(R) 皮下注) の薬理学的特徴および臨床試験成績. 日本薬理学雑誌 136 : 233-241, 2010.

Medical*Online